Published in Cancer Weekly, December 13th, 2005
According to recent research from the United States, "Taxanes are commonly used anticancer agents with a potential of producing an allergic or HSR. We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel."
"Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.